Margaret Frey, DO
Neurology · Owosso, MINPI 1215134101
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $232,234 of the $321,408 with a category attached, or 72.3%. Biogen accounts for 82.5% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $116,425 and has fallen 81.4% since, to $21,655 in 2025. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 621 payments — averaging $517.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$265K
- AbbVie$32K
- Genentech USA, Inc.$12K
- Grifols USA, LLC$6K
- Genentech, Inc.$3K
- Livanova USA, Inc.$1K
- plus $2K from 35 others
Across 5 payments — averaging $43,985 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$218K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$40,91713%
- Speaking & faculty fees$232,23472%
- Travel & lodging$39,29312%
- Food & beverage$8,6543%
- Education$3100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$321,408 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 44 | $1,164,666 |
| Radicava OrsEdaravone | 38 | $593,506 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 60 | $568,406 |
| SkyclarysOmaveloxolone | 12 | $387,212 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 44 | $259,210 |
| NuplazidPimavanserin Tartrate | 14 | $70,812 |
| BriviactBrivaracetam | 21 | $55,998 |
| Emgality PenGalcanezumab-Gnlm | 76 | $53,229 |
| UbrelvyUbrogepant | 26 | $30,940 |
| QuliptaAtogepant | 24 | $25,520 |
| Nurtec OdtRimegepant Sulfate | 16 | $24,696 |
| XcopriCenobamate | 15 | $18,985 |
| Tetrabenazine | 26 | $8,947 |
| Lacosamide | 55 | $6,819 |
| Riluzole | 13 | $5,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $11,879 | $1,164,66644 claims |
| BiogenSkyclarys | $265,268 | $387,21212 claims |
| Acadia Pharmaceuticals IncNuplazid | $62 | $70,81214 claims |
| AbbVieUbrelvy, Qulipta | $32,351 | $56,46050 claims |
| UCB, Inc.Briviact | $265 | $55,99821 claims |
| PfizerNurtec Odt, Dilantin | $19 | $26,59927 claims |
| SK Life Science, Inc.Xcopri | $103 | $18,98515 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $24 | $2,36827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Owosso
- Robert PaceOwosso$693K
- Rosemarie WalchOwosso$563K
- Jeanie CoteOwosso$563K
- Rany AburashedOwosso$440K
- Cara LeahyOwosso$185K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.